About everolimus bht
mTOR inhibitor; immunosuppressant and antineoplastic
Used for
- Certain advanced breast, kidney, and neuroendocrine cancers
- Subependymal giant cell astrocytoma associated with tuberous sclerosis
- Renal angiomyolipoma associated with tuberous sclerosis
Usual adult dose
Usually 10 mg once daily for cancer; some conditions require individualized dosing.
Usual dose in children
For tuberous sclerosis-related brain tumors, dosing is based on body surface area and blood levels.
Common side effects
- Mouth sores
- Infections
- Rash
- Diarrhea or nausea
Important warnings
- Can cause serious infections and reduced blood-cell counts.
- May cause lung inflammation, kidney problems, or high blood sugar and cholesterol.
- Can impair wound healing; surgery may require treatment interruption.
- Avoid live vaccines; monitor blood counts and organ function.
Pregnancy
May harm an unborn baby. Effective contraception is recommended during treatment and for 8 weeks afterward.
Breastfeeding
Breastfeeding is not recommended during treatment or for 2 weeks after the last dose.
Interactions
- Strong CYP3A4 or P-glycoprotein inhibitors can raise everolimus levels.
- Strong CYP3A4 or P-glycoprotein inducers can lower everolimus levels.
- Grapefruit may increase levels; avoid it.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.